ClinicalTrials.gg
Status unknownNCT04326959KeloidUpdated Jul 15, 2020

Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid

A Phase 1/2 interventional study of Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium and Conditioned Medium in Keloid, sponsored by PT. Prodia Stem Cell Indonesia. Status unknown. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-15.

Sponsored by PT. Prodia Stem Cell Indonesia · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta and planned from June 2020 to December 2020. Clinical trials of Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs) and Conditioned Medium Umbilical Cord-Mesenchymal Stem Cells (CM UC-MSCs) for Keloid were designed in three groups. Group 1 injected with The UC-MSCs at a dose of 2 million cells / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection and booster with CM UC-MSCs at a dose of 1 cc / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection and booster with CM UC-MSCs at the same dose 3 weeks later. Group 3 injected with Triamcinolon acetonide (TA) at a dose of 40 mg / cc / cm3 using 1 cc (27 G) syringe and booster with TA at 3 weeks later. The study subjects each group amounted to 7 patients suffering from Keloid. Patients were evaluated for 3 months after injection.

02

Conditions studied

  • Keloid

Browse trials for

Keywords

  • Keloid
  • Allogeneic Mesenchymal Stem Cells
  • Umbilical Cord
  • Conditioned Medium
03

In context

Keloid

139 studies on the registry are indexed under Keloid; 26 are open to participants now.

This study's planned enrollment of 24 is below the median of 30 across 110 interventional studies indexed under Keloid.

Browse Keloid studies →

Lead sponsor

PT. Prodia Stem Cell Indonesia is the lead sponsor of 16 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgery history of more than 3 months
  • Has keloid that the maximum size is 15 cm and thickness is 3-5 mm

Exclusion criteria

Exclusion Criteria:

  • Patients with kidney failure
  • Pregnancy
  • Breastfeeding
  • Liver dysfunction
  • Blood disorders
  • Currently receiving therapy (chemotherapy or )
  • Refusing to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    UC-MSCs + CM

    A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.

    Biological: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium · Biological: Conditioned Medium

  • Experimental
    CM + CM

    A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.

    Biological: Conditioned Medium

  • Experimental
    Triamcinolon acetonide

    A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient.

    Biological: Triamcinolone Acetonide

Interventions

  • BiologicalUmbilical Cord-Mesenchymal Stem Cells and Conditioned Medium

    Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.

  • BiologicalConditioned Medium

    Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.

    Also known as: Secretome

  • Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.

06

What researchers measure

Primary outcomes

  1. Alfa SMA-1

    Biomarker

    Time frame: 3 month after injection

  2. Collagen type 1

    Biomarker

    Time frame: 3 moth after injection

Secondary outcomes

  1. Core Biopsy/Histopathology

    Too evaluate histology of keloid

    Time frame: 3 month after injection

  2. Ultrasonography

    To see image inside the body

    Time frame: 3 month after injection

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2020; primary completion for Sep 2020, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Mar 30, 2020
StartEst.
Sep 1, 2020
Primary completionEst.
Sep 8, 2020
CompletionEst.
Dec 1, 2020
Last update
Jul 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04326959
Lead sponsor
PT. Prodia Stem Cell Indonesia
Responsible party
Sponsor
First posted
Mar 30, 2020
Start date
Sep 1, 2020 (estimated)
Primary completion
Sep 8, 2020 (estimated)
Completion
Dec 1, 2020 (estimated)
Last update
Jul 15, 2020

Study contacts

Anastasia Dessy Harsono, Master
Contact
anastasia.bedahplastik@gmail.com
087888363270
Cynthia Retna Sartika, Doctor
Contact
c.sartika@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion